REGN banks on Dupixent and Eylea HD gains to offset Eylea's decline while oncology wins strengthen its diversified pipeline.

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from ...

At the same time, more than half of the US-listed stocks covered by Morningstar that reported earnings as of Aug. 11 beat ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the top most undervalued biotech stocks to buy now. Guggenheim ...

CNW/ - (TSX: DHT.UN) (TSX: DHT.U) ("DRI Healthcare") today announced its financial results for the quarter ended June 30, ...

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...

Regeneron Court Permits Government to Pursue False Certification Theory - On August 4, the district court in the closely ...

Second-Quarter 2025 and Recent Selected Highlights: <li /> Total revenues of $63.7 million, a 30% increase over $48.

Strong performance driven by over 200% growth in product revenues year-on-year Best quarter in Alvotech's history in terms of operating cash flowsContinued expansion of commercial partnerships for pip ...

Bayer AG agreed to pay Kumquat Biosciences Inc. as much as $1.3 billion to gain a potential new cancer medicine and boost its pharma division’s growth prospects.